| Record ID | marc_university_of_toronto/uoft.marc:4522427148:1527 |
| Source | University of Toronto |
| Download Link | /show-records/marc_university_of_toronto/uoft.marc:4522427148:1527?format=raw |
LEADER: 01527cam 2200325 a 4500
001 ocm51856393
005 20031015072102.0
008 030115s2002 onca b f000 0 eng
020 $a1894620577
042 $apcc
060 00 $a2003 A-561
060 10 $aWK 825$bE27 2002
245 00 $aEfficacy of rosiglitazone and pioglitazone compared to other anti-diabetic agents :$bsystematic review and budget impact analysis /$cMichel Boucher ... [et al.].
260 $aOttawa :$bCanadian Coordinating Office for Health Technology Assessment,$c[2002]
300 $ax, 76 p. :$bill.
490 1 $aTechnology report ;$vissue 29
500 $a"October 2002."
504 $aIncludes bibliographical references (p. 52-57).
650 0 $aDiabetes$xChemotherapy.
650 0 $aHypoglycemic agents.
650 0 $aCost effectiveness.
650 12 $aDiabetes Mellitus$xdrug therapy.
650 12 $aHypoglycemic Agents$xtherapeutic use.
650 22 $aCost-Benefit Analysis.
700 1 $aBoucher, Michel,$cB Pharm.
710 2 $aCanadian Coordinating Office for Health Technology Assessment.
830 0 $aTechnology report (Canadian Coordinating Office for Health Technology Assessment) ;$vissue 29.
949 $aRC661 .A1 E33 2002$wLC$c1$i5000529-1001$lSTACKS$mGERSTEIN$rY$sY$tBOOK$u15/10/2003
949 $aRC661 .A1 E33 2002$wLC$c1$i31761054808159$d1/12/2003$e29/10/2003$lSTACKS$mGERSTEIN$n1$rY$sY$tBOOK$u15/10/2003
949 $aRC661 .A1 E33 2002$wLC$c2$i31761059641522$d13/4/2004$e29/10/2003$lSTACKS$mGERSTEIN$n1$rY$sY$tBOOK$u15/10/2003